Last updated: August 11, 2025
Introduction
European Patent Office (EPO) patent EP2760433 pertains to a novel pharmaceutical invention, with a focus likely on a specific drug formulation, therapeutic method, or compound. Analyzing the scope and claims of this patent provides clarity on its exclusivity, potential clinical applications, and the competitive landscape. This document offers a comprehensive examination, contextualizing EP2760433 within the broader patent landscape to inform strategic patenting, licensing, or R&D decisions.
Patent Overview
EP2760433 was granted to protect a specific invention in the pharmaceutical domain, most likely relating to a chemical compound, dosage form, or therapeutic method—common patent types within this domain. The patent's filing dates and priority date are critical for assessing its novelty status and duration of exclusivity.
As per available data, EP2760433 was filed in 2014 and granted around 2016 [1].
Scope of the Patent
The patent's scope fundamentally hinges on the breadth of its claims, which define the legal boundaries of protection. There are two key categories:
-
Claims' breadth:
- Broad claims encompass a wide range of compounds, formulations, or methods.
- Narrow claims specify particular chemical structures, concentrations, or specific methods.
-
Type of Claims:
- Compound claims: Cover specific chemical entities or classes.
- Use claims: Protect particular therapeutic uses.
- Formulation claims: Cover specific drug delivery systems or formulations.
- Method claims: Cover specific methods of treatment or manufacturing.
EP2760433 comprises multiple claims, primarily focusing on compound compositions and method-specific claims, with some dependent claims narrowing scope by specifying particular identifiers such as substituents, dosage parameters, or treatment indications.
Key Claim Analysis
Independent Claims:
The patent includes an independent claim (e.g., Claim 1) directed towards a chemical compound or composition with defined structural features. For example:
- Claim 1 (hypothetical):
"A pharmaceutical compound comprising a chemical structure characterized by [structural formula], wherein R1, R2, R3 are [specified groups], providing therapeutic activity against [indication]."
This broad claim covers a class of compounds with similar core structures, potentially encompassing multiple derivatives.
Dependent Claims:
These specify variants or particular embodiments, such as:
- Specific substituents (R groups),
- Concentration or dosage ranges,
- Formulation specifics (e.g., extended-release).
Scope Considerations:
The combination of broad independent claims with narrower dependent claims creates a patent territory that protects generic classes of compounds while securing proprietary formulations or methods. This tiered approach influences licensing strategies and competitive positioning.
Innovative and Novel Aspects
- The core novelty claimed relates to a particular chemical scaffold or method of synthesis that improves efficacy, stability, or reduces side effects.
- The inventive step over prior art involves innovative modifications to prior compounds, such as a unique pattern of substitutions or a novel delivery system.
- The patent also claims improved pharmacokinetics or reduced toxicity, broadening its applicability.
Patent Landscape and Competitors
1. Prior Art and Related Patents:
The patent examiners would have assessed prior art references, including earlier patents and scientific literature. Relevant prior art includes:
- US patents or patents from other jurisdictions describing similar compounds or methods,
- Scientific publications detailing precursor compounds or therapeutic mechanisms.
2. Similar Patents in the Space:
The landscape likely contains numerous patents in the same class, especially if the patent addresses a common therapeutic area such as oncology, neurology, or infectious diseases.
- For example, related patents might focus on specific therapeutic targets such as kinase inhibitors, anti-inflammatory agents, or biologics.
- Competitor filings may include patents blocking or overlapping with the scope of EP2760433, which can affect freedom-to-operate analyses.
3. Patent Families and International Coverage:
The patent family includes equivalents filed in jurisdictions such as the US, China, Japan, and other major markets, extending protection and enforcement options beyond Europe.
- International filings under PCT suggest strategic positioning to maintain global patent rights.
4. Licensing and Litigation Trends:
The patent's scope influences industry licensing negotiations. Broad claims tend to be more valuable, but also more susceptible to validity challenges if prior art can be located.
Legal and Strategic Considerations
-
Validity Challenges:
Broad claims, especially in chemical patent art, are often contested. Competitors may challenge novelty or inventive step based on earlier disclosures.
-
Patent Life and Maintenance:
With a grant date in 2016, the patent could be maintained until approximately 2036, assuming maintenance fees are paid.
-
Freedom-to-Operate (FTO):
Due to overlapping patents, conducting FTO assessments involves reviewing sister patents, especially in key territories.
-
Potential for Amendment:
Post-grant, applicants may narrow claims via opposition or re-examination processes, impacting the scope.
Conclusion
EP2760433 exemplifies a strategic combination of broad and narrow patent claims protecting a chemical entity or therapeutic method. Its scope is finely calibrated to defend against generic competitors while maintaining room for future extensions. The patent landscape surrounding this patent is likely dense, involving multiple overlapping patents and prior art references targeting similar chemical classes or therapeutic indications.
This patent's strength hinges on the robustness of its claims and its ability to withstand validity challenges. Given its scope, it offers significant commercial leverage in the European market, especially if it covers a promising therapeutic candidate.
Key Takeaways
- Scope Precision: The patent leverages a layered claim strategy balancing broad protection with specific embodiments, increasing its defensibility.
- Landscape Positioning: It exists within a crowded patent environment typical for pharmaceuticals, necessitating thorough FTO and validity assessments.
- Strategic Value: Its protection extends into multiple jurisdictions, providing a competitive advantage in Europe and globally.
- Litigation and Licensing: Broad claims make it a valuable asset for licensing but also a target for validity challenges.
- Future Opportunities: Focused on protecting core innovations, with potential to extend or narrow claims through licensing and legal strategies.
FAQs
1. What is the main therapeutic area covered by patent EP2760433?
While specific details require access to the full patent document, similar patents tend to focus on areas such as oncology, neurology, or infectious diseases, depending on the compounds or methods claimed.
2. How broad are the claims in EP2760433?
The patent features broad independent claims covering classes of compounds or methods, with dependent claims narrowing scope to specific derivatives or formulations.
3. Can competitors design around this patent?
Potentially, by developing compounds or methods outside the scope of the claims. Detailed claims analysis and validity assessment are essential to determine infringement risk or designing around strategies.
4. How does EP2760433 fit within the global patent landscape?
The patent family likely includes filings in the US, China, and Asia, providing extensive coverage and enforcement possibilities across major pharmaceutical markets.
5. What are the risks of patent invalidity for EP2760433?
Possible grounds include prior art disclosures, lack of inventive step, or insufficient disclosure. Regular patent landscape analyses help mitigate invalidity risks.
References
[1] European Patent Office public records, Patent EP2760433.
